Axial spondyloarthritis (axSpA) is a disease concept entailing the disease entities ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
According to the modified New York criteria, radiographic signs of sacroileitis are mandatory whilst nr-axSpA lack these and is instead, according to the ASAS classification criteria, classified based on imaging with MRI of the sacroiliac joints and/or based on a combination of HLA-B27 positivity in combination with clinical parameters.
However, both AS och nr-axSpA have an equal burden of disease. Patients with nraxSpA failing conventional treatment with at least 2 different NSAIDs and concomitantly having high disease activity are according to EULAR guidelines eligible for biologic treatment. Besides TNF-inhibition, also IL17-inhibition is now indicated for treatment of nraxSpA.
Novartis invites you to a streamed lecture with Lennart Jacobsson, Sr Professor Rheumatology at Sahlgrenska academy, Gothenburg, Sweden and Doctor Giovanni Cagnotto, Skane University Hospital, Malmö, Sweden who was a principal investigator in the PREVENT study, will give a lecture on nr-axSpA and the results from the PREVENT study, studying the efficacy and safety of IL-17A inhibitor, secukinumab in patients with nr-axSpA.
Sr professor Lennart Jacobsson, Sahlgrenska Academy
Dr Giovanni Cagnotto, Skane University Hospital
Thursday September 17th at 16:00-17:00 CET
Webstreaming from film studio in Malmö.
- Participation in the meeting requires approval from the head of department.
- Participation in the meeting is free of costs.